Management of Cutaneous Calciphylaxis
Authors:
Open Access
- 30 September 2020
- journal article
- review article
- Published by Springer Nature in Advances in Therapy
- Vol. 37 (12) , 4797-4807
Abstract
Calciphylaxis is a deadly, painful disease with a 1-year mortality of up to 50%. The disease is commonly associated with patients with end-stage kidney disease (ESKD), but it can manifest in non-uremic patients as well. In patients who are undergoing dialysis, the incidence of calciphylaxis can range from 0.04% to 4%. The progressive arterial calcification seen in calciphylaxis can affect multiple body organs, including the skin, brain, lungs, and muscle. In cutaneous calciphylaxis, painful and non-healing nodules, plaques, and ulcers may appear, increasing morbidity for patients. Diagnosis can be difficult, and the condition can clinically appear similar to other dermatological diseases, especially in non-uremic patients. Currently, skin biopsy with histological analysis is the most reliable method to help diagnose the condition. In certain cases, the use of medical imaging may be helpful. Treatment of pain in this condition can be difficult and should be multimodal and include wound care as well as modification of risk factors. Analgesic options include opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), as well as analgesic options that are targeted for specific patients. There are currently multiple clinical trials underway that are studying targeted therapies for this condition.Keywords
This publication has 45 references indexed in Scilit:
- Update on cutaneous calciphylaxisIndian Journal of Dermatology, 2013
- Novel insights into osteogenesis and matrix remodelling associated with calcific uraemic arteriolopathyNephrology Dialysis Transplantation, 2012
- Adipose Tissue Vascularization: Its Role in Chronic InflammationCurrent Diabetes Reports, 2011
- Determinants of survival in patients with calciphylaxis: A multivariate analysisSurgery, 2009
- Inhibition of Receptor Activator of NF-κB Ligand by Denosumab Attenuates Vascular Calcium Deposition in MiceThe American Journal of Pathology, 2009
- Calciphylaxis: Natural history, risk factor analysis, and outcomeJournal of the American Academy of Dermatology, 2007
- Symptomatic Management of Calciphylaxis: A Case Series and Review of the LiteratureJournal of Pain and Symptom Management, 2006
- Therapy for calciphylaxis: An outcome analysisSurgery, 2003
- Distal calcific uremic arteriolopathy in a hemodialysis patient responds to lowering of Ca P product and aggressive wound careClinical Nephrology, 2002
- Calciphylaxis is usually non-ulcerating: Risk factors, outcome and therapyKidney International, 2002